 | |
| Clinical data | |
|---|---|
| Other names | SH-434; 17α-Propylmesterolone; 17β-Hydroxy-1α-methyl-17α-propyl-5α-androstan-3-one |
| Routes of administration | Topical |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.071.904 |
| Chemical and physical data | |
| Formula | C23H38O2 |
| Molar mass | 346.555 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Rosterolone (INNTooltip International Nonproprietary Name) (developmental code nameSH-434), also known as17α-propylmesterolone or1α-methyl-17α-propyl-5α-androstan-17β-ol-3-one, is asteroidal antiandrogen which was first described in 1984 and was developed fortopical administration but was never marketed.[1][2] It has shown someefficacy in the treatment ofacne, and lacks systemic effects with either topical or systemic administration.[3][1][2] Rosterolone is a derivative ofmesterolone, which, in contrast, is anandrogen andanabolic steroid.[citation needed]
 | Thisdermatologicdrug article is astub. You can help Wikipedia byexpanding it. |
